China’s life sciences boom: Navigating risk for growth

Wednesday, March 11, 2026

China’s life sciences sector is experiencing rapid expansion, driven by innovation, regulatory reforms, and increasing global collaboration. For companies and investors, this growth could present significant opportunities – and complex challenges. Geopolitical shifts, evolving trade policies, and regulatory uncertainties could impact market entry and long-term strategy.

A panel of DLA Piper attorneys explored:

• Key drivers of growth in China’s life sciences industry
• Strategic considerations for mergers and acquisitions, partnerships, licensing, and investment
• Managing geopolitical and compliance risks in cross-border transactions
• Changes resulting from the BIOSECURE Act and the operational steps life sciences and investors can take now

This session provided practical insights for life sciences executives, investors, and legal teams seeking to engage with China’s dynamic market while mitigating risk.

For more information
Please contact Sarah Mattern.